Program Description
Hypertrophic cardiomyopathy (HCM) is an inherited cardiovascular disease that remains underdiagnosed. In HCM, the left ventricle becomes smaller, stiffer, and unable to fill with blood, causing a reduction in the heart’s ability to pump and resulting in symptoms such as chest pain, dizziness, dyspnea, and syncope. Traditional therapies such as beta blockers, calcium channel blockers, and disopyramide are used for symptom control. However, in recent years, the discovery of the genetic pathology of HCM has led to the development of several targeted therapies with the first cardiac myosin inhibitor, mavacamten, receiving FDA approval in 2022 and another agent, aficamten under investigation. As integral members of the health care team, pharmacists must understand goals of therapy with novel agents, including improving exercise capacity and relieving hypercontractility symptoms, and the potential role of these agents in improving clinical outcomes in patients with HCM. This webinar will review guidelines for the management of HCM and clinical safety and efficacy data of novel and emerging therapies for HCM to equip pharmacists to educate patients and other health care team members about advances in HCM treatment and management.
Target audience: Health-system and specialty pharmacists
Type of activity: Application
Release date: November 15, 2022
Expiration date: January 15, 2023
Time to complete activity: 1 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the pathophysiology, specific risk factors, and typical presentation of patients with hypertrophic cardiomyopathy (HCM)
- Analyze mechanism of action, safety and efficacy data, and recommended management strategies from evidence-based guidelines for novel therapies for HCM to address underdiagnosis and the unmet clinical needs of patients
- Illustrate approaches for pharmacists to collaborate with the multidisciplinary care team in the management of adverse effects, patient counseling, and monitoring of patients with HCM
Ryan D’Angelo, PharmD, BCPS
Clinical Pharmacy Specialist – Cardiology
Department of Pharmacy
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-433-L01-P. The activity is available for CE credit through January 15, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Ryan D’Angelo, PharmD, BCPS
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS, CHCP; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms